

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM381374

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
EMMAUS LIFE SCIENCES, INC.		04/18/2016	Corporation: DELAWARE
EMMAUS MEDICAL, INC.		04/18/2016	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	AGILITY CAPITAL II, LLC		
<b>Street Address:</b>	812 Anacapa Street, Suite A		
<b>City:</b>	Santa Barbara		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	93101		
<b>Entity Type:</b>	Limited Liability Company: CALIFORNIA		
<b>PROPERTY NUMBERS Total: 10</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86963532	EMMAUS MEDICAL	
<b>Serial Number:</b>	86963456	EMMAUS	
<b>Registration Number:</b>	3514187	AMINOPURE	
<b>Serial Number:</b>	85582108	NOSIC	
<b>Serial Number:</b>	85582217	NOSIK	
<b>Serial Number:</b>	85582244	EMMAUS	
<b>Serial Number:</b>	85585574	EMMAUS MEDICAL	
<b>Registration Number:</b>	3544782	NUTRESTORE	
<b>Registration Number:</b>	3727236	NUTRESTORE	
<b>Serial Number:</b>	85912407	RIDSIC	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6506440520		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6506483802		
<b>Email:</b>	PATTY@PATTYCHENG.COM		
<b>Correspondent Name:</b>	PATTY CHENG		
<b>Address Line 1:</b>	2625 Middlefield Rd., #215		

OP \$265.00 86963532

**Address Line 4:** Palo Alto, CALIFORNIA 94306

**ATTORNEY DOCKET NUMBER:** 3-1015

**NAME OF SUBMITTER:** PATTY CHENG

**SIGNATURE:** /s/ Patty Cheng

**DATE SIGNED:** 04/21/2016

**Total Attachments: 11**

source=Emmaus - IPSA - executed#page1.tif  
source=Emmaus - IPSA - executed#page2.tif  
source=Emmaus - IPSA - executed#page3.tif  
source=Emmaus - IPSA - executed#page4.tif  
source=Emmaus - IPSA - executed#page5.tif  
source=Emmaus - IPSA - executed#page6.tif  
source=Emmaus - IPSA - executed#page7.tif  
source=Emmaus - IPSA - executed#page8.tif  
source=Emmaus - IPSA - executed#page9.tif  
source=Emmaus - IPSA - executed#page10.tif  
source=Emmaus - IPSA - executed#page11.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** is entered into as of April 18, 2016 by and between **AGILITY CAPITAL II, LLC**, a California limited liability company ("**Lender**") and Emmaus Life Sciences, Inc., a Delaware corporation ("**Borrower**") and Emmaus Medical, Inc. ("**Guarantor**"). Each of Borrower and Guarantor are also referred to as a "**Grantor**".

### RECITALS

Lender has agreed to make certain advances of money and to extend certain financial accommodation to Borrower in the amounts and manner set forth in that certain Loan Agreement by and between Lender and Borrower (as amended from time to time, the "**Loan Agreement**") dated on or about the date hereof and as amended from time to time. In connection therewith, Guarantor entered into that certain Unconditional Guaranty dated on or about the date hereof (the "**Guaranty**") to guaranty the obligations owing under the Loan Agreement, and secure its obligations under the Guaranty with the assets of the Guarantor. Capitalized terms used herein have the meaning assigned in the Loan Agreement. Lender is willing to make the credit extensions to Borrower, but only upon the condition, among others, that Grantors grant to Lender a security interest in all of each Grantor's right title, and interest in, to and under all of the Collateral whether presently existing or hereafter acquired.

**NOW, THEREFORE**, each Grantor agrees as follows:

### AGREEMENT

To secure performance of each Grantor's obligations under the Loan Agreement or Guaranty, as applicable, each Grantor grants to Lender a security interest in all of such Grantor's right, title and interest in Grantor's intellectual property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits). This security interest is granted in conjunction with the security interest granted to Lender under the Loan Agreement and the Guaranty. Each right, power and remedy of Lender provided for herein shall not preclude the simultaneous or later exercise by Lender of any or all other rights, powers or remedies.


[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed as of the first date written above.


Address of Grantors:

EMMAUS LIFE SCIENCES, INC.

21250 Hawthorne, Suite 800  
Torrance, California 90503  
Attn: Peter Ludlum

By:   
Title: CEO


EMMAUS MEDICAL, INC.

By:   
Title: COO

Address of Lender:

AGILITY CAPITAL II, LLC

812 Anacapa Street, Suite A  
Santa Barbara, CA 93101

By:   
Title: MANAGING MEMBER

**EXHIBIT A**

**Copyrights**

Please Check if No Copyrights Exist

**Title**

**Registration Number**

**Registration Date**

---

**EXHIBIT B**  
**Patents**

**Our Ref: None**

Country/Region: United States  
Patent No: 5,693,671  
Filed: May 1, 1996  
Priority: None  
Title: L-Glutamine Therapy for Sickle Cell Diseases and Thalassemia  
Status: Issued December 2, 1997; in-licensed from the UC; all maintenance fees paid.

**Our Ref: EM-001.01**

Country/Region: United States  
Type: Provisional Patent Application  
Appl. No.: 61/629,633  
Filed: November 21, 2011  
Priority: None  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Expired.

**Our Ref: EM-001.02**

Country/Region: United States  
Type: Non-provisional Patent Application  
Appl. No.: 13/694,301  
Filed: November 17, 2012  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Pending; a Final Office Action rejecting all claims has been issued by the USPTO; a Request for Continued Examination will be filed allowing pursuit of modified claims.

**Our Ref: EM-001.20**

Country/Region: Patent Cooperation Treaty  
Type: PCT Application  
Appl. No.: PCT/US2012/000557  
Filed: November 17, 2012  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Expired.

**Our Ref: EM-001.21**

Country/Region: Europe  
Type: Regional Phase Filing  
Appl. No.: 12850971.8  
Filed: May 21, 2014  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Pending.

**Our Ref: EM-001.28**

Country/Region: Brazil  
Type: National Phase Filing  
Appl. No.: BR 1 2014 011898 1  
Filed: May 16, 2014  
Priority: US Appl. No. 61/629,633  
Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms  
Status: Pending.

**Our Ref: EM-001.29**

Country/Region: India

Type: National Phase Filing

Appl. No.: 1037/KOLNP/2014

Filed: May 15, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms

Status: Pending.

**Our Ref: EM-001.39**

Country/Region: Philippines

Type: National Phase Filing

Appl. No.: 1-2014-501052

Filed: May 9, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms

Status: Pending.

**Our Ref: EM-001.40**

Country/Region: China

Type: National Phase Filing

Appl. No.: 201280056399

Filed: May 20, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms

Status: Pending.

**Our Ref: EM-001.41**

Country/Region: Indonesia

Type: National Phase Filing

Appl. No.: P-00201402912

Filed: May 16, 2014

Priority: US Appl. No. 61/629,633

Title: Methods and Compositions for the Treatment of Diabetes and Related Symptoms

Status: Pending.

**Our Ref: EM-002.01**

Country/Region: United States

Type: Provisional Patent Application

Appl. No.: 61/630,831

Filed: December 19, 2011

Priority: None

Title: Methods and Compositions for the Treatment of Diverticulosis

Status: Expired.

**Our Ref: EM-002.02**

Country/Region: United States

Type: Non-provisional Patent Application

Appl. No.: 13/694,592

Filed: December 19, 2011

Priority: US Appl. No. 61/630,831

Title: Methods and Compositions for the Treatment of Diverticulosis

Status: Pending; a Final Office Action rejecting all claims has been issued by the USPTO; a Request for Continued Examination will be filed allowing pursuit of modified claims.

**Our Ref: EM-002.20**

Country/Region: Patent Cooperation Treaty  
Type: PCT Application  
Appl. No.: PCT/US2012/000576  
Filed: December 14, 2012  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Expired.

**Our Ref: EM-002.21**

Country/Region: Europe  
Type: Regional Phase Filing  
Appl. No.: 12860587.0  
Filed: June 25, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.24**

Country/Region: Australia  
Type: National Phase Filing  
Appl. No.: 2012355956  
Filed: June 9, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.26**

Country/Region: Mexico  
Type: National Phase Filing  
Appl. No.: MX/a/2014/007382  
Filed: June 18, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.28**

Country/Region: Brazil  
Type: National Phase Filing  
Appl. No.: BR 11 2014 014765 5  
Filed: June 16, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.29**

Country/Region: India  
Type: National Phase Filing  
Appl. No.: 1255/KOLNP/2014  
Filed: June 10, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.



**Our Ref: EM-002.38**

Country/Region: Korea  
Type: National Phase Filing  
Appl. No.: 10-2014-7016785  
Filed: June 19, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.40**

Country/Region: China  
Type: National Phase Filing  
Appl. No.: To Be determined  
Filed: June 18, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.41**

Country/Region: Indonesia  
Type: National Phase Filing  
Appl. No.: P-00201403584  
Filed: June 18, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-002.43**

Country/Region: Russia  
Type: National Phase Filing  
Appl. No.: 2014123433  
Filed: June 9, 2014  
Priority: US Appl. No. 61/630,831  
Title: Methods and Compositions for the Treatment of Diverticulosis  
Status: Pending.

**Our Ref: EM-003.01**

Country/Region: United States  
Type: Invention Disclosure  
Appl. No.: To Be Determined  
Filed: To Be Determined  
Priority: None  
Title: To Be Determined  
Status: Invention disclosure directed to combination therapy involving glutamine and alkali therapy (*e.g.*, sodium bicarbonate). Application in process.

**Our Ref: EM-004.01**

Country/Region: United States  
Type: Invention Disclosure  
Appl. No.: To Be Determined  
Filed: To Be Determined  
Priority: None  
Title: To Be Determined  
Status: Invention disclosure directed to combination therapy involving glutamine and hydroxyurea. Application in process.

**Our Ref: EM-005.01**

Country/Region: United States

Type: Invention Disclosure

Appl. No.: To Be Determined

Filed: To Be Determined

Priority: None

Title: To Be Determined

Status: Invention disclosure directed to combination therapy involving glutamine and various agents, including statins, nitric oxide and nitric oxide stimulating/releasing compounds, and agents that boost production of fetal hemoglobin. Application in process.

**Our Ref: EM-006.01**

Country/Region: United States

Type: Invention Disclosure

Appl. No.: To Be Determined

Filed: To Be Determined

Priority: None

Title: To Be Determined

Status: Invention disclosure directed to reduction of side effects in children based on a dosing regimen of glutamine. Application in process.

## EXHIBIT C

### Trademarks

Country/Region: United States  
Type: Trademark for EMMAUS MEDICAL  
Application No.: 86963532  
Filing Date: April 4, 2016

Country/Region: United States  
Type: Trademark for EMMAUS  
Application No.: 86963456  
Filing Date: April 4, 2016

**Our Ref: EM-501.00**

Country/Region: United States  
Type: Trademark for AMINOPURE  
Registration No.: 3,514,187  
Reg. Date: October 7, 2008  
Status: Registered; Declaration of Use due, without extension, October 7, 2014.

**Our Ref: EM-501.25**

Country/Region: Taiwan  
Type: Trademark for AMINOPURE  
Registration No.: 01546380  
Reg. Date: November 1, 2012  
Status: Registered; Extension due October 31, 2022.

**Our Ref: EM-501.36**

Country/Region: Ghana  
Type: Trademark for AMINOPURE  
Application No.: 000128/2012  
Status: Allowed, awaiting certificate of registration.

**Our Ref: EM-501.37**

Country/Region: Kenya  
Type: Trademark for AMINOPURE  
Application No.: 77713  
Status: Published for opposition.

**Our Ref: EM-501.38**

Country/Region: Korea  
Type: Trademark for AMINOPURE  
Registration No.: 45-0042982  
Reg. Date: January 3, 2013  
Status: Registered; Extension due January 4, 2022.

**Our Ref: EM-501.39**

Country/Region: Philippines  
Type: Trademark for AMINOPURE  
Registration No.: 4-2012-000514  
Reg. Date: April 26, 2012  
Status: Registered; Declaration of Use due January 13, 2015.

**Our Ref: EM-501.40**

Country/Region: China  
Type: Trademark for AMINOPURE  
Application No.: To Be Determined  
Status: Filed; pending.

**Our Ref: EM-501.41**

Country/Region: Indonesia  
Type: Trademark for AMINOPURE  
Application No.: To Be Determined  
Status: Filed; pending.

**Our Ref: EM-501.42**

Country/Region: Malaysia  
Type: Trademark for AMINOPURE  
Application No.: To Be Determined  
Status: Filed; pending.

**Our Ref: EM-502.00**

Country/Region: United States  
Type: Trademark for NOSIC  
Application No.: 85-582,108  
Status: Allowed; Statement of Use or extension due August 4, 2014. This case was the subject of an opposition proceeding, Opposition 91211282, which was terminated on December 21, 2013.

**Our Ref: EM-503.00**

Country/Region: United States  
Type: Trademark for NOSIK  
Application No.: 85-582,217  
Status: Allowed; Statement of Use or extension due September 11, 2014. This case was the subject of an opposition proceeding, Opposition 91211284, which was terminated on January 24, 2014.

**Our Ref: EM-504.00**

Country/Region: United States  
Type: Trademark for EMMAUS  
Application No.: 85-582,244  
Status: Allowed; Statement of Use or extension due October 8, 2014.

**Our Ref: EM-504.00**

Country/Region: United States  
Type: Trademark for EMMAUS MEDICAL  
Application No.: 85-585,574  
Status: Allowed; Statement of Use or extension due October 8, 2014.

**Our Ref: EM-506.00**

Country/Region: United States  
Type: Trademark for NUTRESTORE  
Registration No.: 3,544,782  
Reg. Date: December 9, 2008  
Status: Registered; Declaration of Use due, without extension, December 9, 2014.

**Our Ref: EM-507.00**

Country/Region: United States  
Type: Trademark for NUTRESTORE (stylized)  
Registration No.: 3,727,236  
Reg. Date: October 6, 2009

Status: Registered; Declaration of Use due, without extension, October 6, 2015.

**Our Ref: EM-508.00**

Country/Region: United States

Type: Trademark for RIDSIC

Application No.: 85-912,407

Status: Allowed; Statement of Use or extension due December 3, 2014.